Genentech Files Second Complaint Over Amgen’s Avastin Biosimilar
Genentech filed a second sealed complaint in Delaware against Amgen over its biosimilar for Avastin (bevacizumab).
Genentech filed a sealed complaint earlier this month in the same jurisdiction claiming Amgen’s Mvasi (bevacizumab-awwb) infringed on 24 patents.
The new complaint adds a 25th patent to the claim.
Two weeks ago, Amgen asked the U.S. District Court for the Central District of California for a declaratory judgment that Mvasi does not violate any of Genentech’s 27 Avastin-related patents.